Masami Nakai
Otsuka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Work productivity by diseases diagnosed among workers: a study using large-scale claims data and survey data of workers in Japan.
Journal: Journal of occupational health
Published: March 17, 2025
Brexpiprazole's impacts on patients and caregivers in agitation in Alzheimer's dementia.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: February 28, 2025
Long-term safety and tolerability of brexpiprazole for Japanese patients with agitation in Alzheimer's disease dementia: A multicenter, open-label study.
Journal: Journal of Alzheimer's disease reports
Published: November 25, 2024
Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: June 17, 2024
Quality of life and work productivity and activity impairment among online survey respondents with migraine across a range of headache frequency.
Journal: Frontiers in neurology
Published: May 30, 2024
Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Journal: Neurology and therapy
Published: April 11, 2023
A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home.
Journal: Expert opinion on drug safety
Published: December 29, 2022
Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials.
Journal: Journal of pain research
Published: October 26, 2022
Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials.
Journal: Journal of pain research
Published: October 21, 2022
Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients.
Journal: The journal of headache and pain
Published: December 05, 2021
Showing 1-12 of 12
Last Updated: 09/26/2026